Ra Pharmaceuticals (NASDAQ:RARX) Issues Earnings Results

Ra Pharmaceuticals (NASDAQ:RARX) released its quarterly earnings results on Thursday. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05), Fidelity Earnings reports. The business had revenue of $3.00 million during the quarter.

Shares of NASDAQ RARX traded up $0.05 during mid-day trading on Friday, hitting $46.82. The company had a trading volume of 413,300 shares, compared to its average volume of 652,991. The company has a market capitalization of $2.21 billion, a PE ratio of -22.73 and a beta of 1.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.30 and a quick ratio of 15.30. Ra Pharmaceuticals has a 1-year low of $11.27 and a 1-year high of $47.35. The business’s 50-day simple moving average is $37.65 and its 200 day simple moving average is $29.69.

In related news, insider Alonso Ricardo sold 2,285 shares of the stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $46.70, for a total value of $106,709.50. Following the transaction, the insider now owns 6,858 shares of the company’s stock, valued at $320,268.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.26, for a total value of $267,629.70. Following the completion of the transaction, the insider now directly owns 8,521 shares in the company, valued at approximately $215,240.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,475 shares of company stock worth $1,402,939. Insiders own 4.30% of the company’s stock.

RARX has been the topic of a number of research reports. Zacks Investment Research cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 17th. Jefferies Financial Group cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating and set a $48.00 price target on the stock. in a research note on Thursday, October 10th. BidaskClub cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. Stifel Nicolaus cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price objective for the company from $50.00 to $48.00 in a research note on Thursday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $48.00 price objective on shares of Ra Pharmaceuticals in a research note on Friday, October 11th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $45.36.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: Most Volatile Stocks

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.